We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

By LabMedica International staff writers
Posted on 08 Aug 2025

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used in healthcare to estimate cardiovascular risk rely on clinical variables that can be imprecise. Now, a new study has identified blood-based biomarkers that significantly improve the prediction of future cardiovascular disease in this population.

A research team led by Lund University (Lund, Sweden) conducted the study, which focused on DNA methylation as a way to detect epigenetic biomarkers in blood. Researchers tracked 752 newly diagnosed individuals from the diabetes cohort ANDIS (All New Diabetics in Skåne) who had no prior cardiovascular disease. Over 7 years, the researchers followed participants' cardiovascular health and studied chemical changes in their genomes.


Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

The team discovered over 400 sites in the blood where DNA methylation was altered. Of these, 87 sites were used to create a scoring system that assesses individual risk for cardiovascular complications. The test showed a strong negative predictive value, with 96% accuracy in identifying those unlikely to develop heart disease.

These findings, published in Cell Reports Medicine, could transform how clinicians identify at-risk patients. Individuals flagged as high risk could receive earlier support in areas such as diet, exercise, weight control, blood sugar management, and cardiovascular protection. The researchers now aim to develop a clinical kit that allows DNA methylation to be measured through a simple blood sample.

"Healthcare today uses clinical variables such as age, gender, blood pressure, smoking, harmful cholesterol, long-term blood sugar, and kidney function to estimate the risk of future cardiovascular disease, but it is a rather blunt tool. If you add DNA methylation, you have a much better measure of future risk," said Charlotte Ling, senior author of the study. “We therefore want to develop a kit for clinical use, so that a simple blood sample can measure DNA methylation and predict who is at risk of becoming ill using the scoring scale.”

Related Links:
Lund University


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Latest Molecular Diagnostics News

Ultra-Sensitive Mutation Detection Technology to Enable Early Detection of Disease Recurrence
08 Aug 2025  |   Molecular Diagnostics

New Test Provides Accurate PCR results for Four Most Common Respiratory Viruses
08 Aug 2025  |   Molecular Diagnostics

Routine Blood Tests Could Enable Early Detection of COPD
08 Aug 2025  |   Molecular Diagnostics